GS Meneilly, N Greig, H Tildesley, JF … - Diabetes Care, 2003 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—A total of 16 patients with type 2 diabetes who
were being treated with oral hypoglycemic agents were enrolled. Eight patients
(aged 75 ± 2 years, BMI 27 ± 1 kg/m 2 ) remained on usual ... Cited by 58 - Related articles - BL Direct - All 9 versions
- ►diabetesjournals.org [PDF] GS Meneilly, CHS McIntosh, RA Pederson, JF … - Diabetes Care, 2001 - Am Diabetes Assoc In the Presidential Address in June of 1998 (1), I proudly announced that the
recently adopted Five Year Plan of the American Diabetes Association (ADA)
contained the goal of allocating one of ev- ery three dollars of total ... Cited by 10 - Related articles - BL Direct - All 4 versions
- ►endojournals.org GS Meneilly, JD Veldhuis, D Elahi - Journal of Clinical Endocrinology & Metabolism, 2005 - Endocrine Soc Design: Two studies were performed. In the first study, insulin values were
sampled every minute for 1 h under fasting conditions. In the second study,
subjects underwent a 2-h hyperglycemic glucose clamp (glucose 5.4 mM above ... Cited by 12 - Related articles - BL Direct - All 3 versions
- ►physiology.org JM Egan, GS Meneilly, D Elahi - American Journal of Physiology- Endocrinology And …, 2003 - Am Physiological Soc A gut insulinotropic peptide, glucagon-like peptide-1 (GLP-1), when given
continuously subcutaneously, has been shown to be an effective agent to treat
type 2 diabetes. Because of inactivation by dipeptidyl peptidase IV (DPP ... Cited by 80 - Related articles - BL Direct - All 4 versions
- ►diabetesjournals.org M Zander, A Christiansen, S Madsbad, J Juul … - Diabetes care, 2004 - Am Diabetes Assoc RESULTS—Fasting plasma glucose decreased from 13.5 ± 1.2 mmol/l (saline) to
11.7 ± 1.2 (GLP-1) and 11.5 ± 1.2 (pioglitazone) and further decreased to 9.9
± 1.0 (combination) (P < 0.001). Eight-hour mean plasma glucose levels ... Cited by 20 - Related articles - BL Direct - All 9 versions
- ►endojournals.org MA Nauck, MM Heimesaat, K Behle, JJ Holst, … - Journal of Clinical Endocrinology & Metabolism, 2002 - Endocrine Soc Nine healthy volunteers with normal oral glucose tolerance received infusions of
regular insulin (1 mU·kg -1 ·min -1 ) over 360 min on two occasions in the
fasting state. Capillary glucose concentrations were clamped at plateaus of ... Cited by 161 - Related articles - BL Direct - All 4 versions
- ►endojournals.org TP Vahl, BW Paty, BD Fuller, RL Prigeon, DA … - Journal of Clinical Endocrinology & Metabolism, 2003 - Endocrine Soc Glucagon-like peptide 1 (GLP-1) is an insulin secretagogue synthesized in the
intestine and released in response to meal ingestion. It is secreted primarily
in two forms, GLP-1-(7–37) and GLP-1-(7–36)NH 2 , both of which bind to ... Cited by 57 - Related articles - BL Direct - All 6 versions
LL Baggio, JG Kim, DJ Drucker - Diabetes, 2004 - Am Diabetes Assoc Glucagon-like peptide-1 (GLP-1) stimulates glucose-dependent insulin secretion
and inhibits food intake, gastric emptying, and glucagon secretion, actions that
promote reduction of fasting and postprandial glycemia in subjects with ... Cited by 17 - Related articles - BL Direct - All 8 versions
- ►diabetesjournals.org J Larsen, B Hylleberg, K Ng, P Damsbo - Diabetes Care, 2001 - Am Diabetes Assoc RESULTS—For all active treatment groups, the change in average glucose (area
under the curve [AUC] for day 7 minus AUC for day 0 divided by 24 h) was
statistically significantly different from placebo (P ≤ 0.001). The GLP-1 ... Cited by 79 - Related articles - BL Direct - All 6 versions
L Juntti-Berggren, J Pigon, F Karpe, A Hamsten … - Diabetes Care, 1996 - Am Diabetes Assoc OBJECTIVE: To investigate the long-term antidiabetogenic effect of glucagon-like
peptide 1 (GLP-1) and its influence on diabetic dyslipoproteinemia, patients
with NIDDM were treated with GLP-1 subcutaneously for 1 week. RESEARCH ... Cited by 52 - Related articles - BL Direct - All 6 versions
